


INLEXZO™ (gemcitabine intravesical system): An Intravesical Drug Releasing System

Please scan to watch an animation on insertion and removal of TAR-200



Drug Delivery Controlled via an Osmotic Pump¹⁻³



Insertion and Removal Is an In-Office Procedure⁴

Refer to [Instructions for Use](#) for full insertion and removal instructions

1. Insertion


- Gather supplies
- Lubricate** tip of catheter shaft and introduce it into the urethra
- Inject lubricant into end of catheter shaft. Then, **load INLEXZO into the catheter**. Use the second syringe to inject lubricant into end of catheter shaft
- Insert stylet into catheter shaft** until the stylet hub is flush with the proximal end of the catheter shaft
- Remove** catheter shaft and stylet as a single unit

2. Indwelling

- INLEXZO is **freely mobile** within the bladder over the indwelling period

3. Removal

- Removal is performed 3 weeks after insertion
- Insert cystoscope** into bladder. Then, introduce **non-cutting grasping forceps** through cystoscope's working channel
- Grasp INLEXZO** by silicone tubing and nitinol wireform. Do not grasp on or near ends of INLEXZO
- Remove the cystoscope and forceps together** to remove INLEXZO



Ease of Use and Seamless Integration Into Clinical Practice



Rapid in-office procedure^{*3-5}



Utilization of familiar catheterization procedure³



Off-the-shelf room temperature storage and handling³



99% (745/755) Insertion success rate⁶



QoL measures remained stable throughout INLEXZO treatment⁷

Johnson & Johnson

*Insertion/removal by trained personnel takes a few minutes and patients do not need to remain in the clinic after insertion to rotate sides or hold bladder. FDA, Food and Drug Administration.

1. Grimberg DC, et al. *Eur Urol Focus*. 2020;6:620-622. 2. Pons-Faudoa FP, et al. *Biomed Microdevices*. 2019;21:47. 3. INLEXZO® (Gemcitabine intravesical system) [US Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2025. 4. INLEXZO® (Gemcitabine intravesical system) [Instructions for Use]. Horsham, PA: Janssen Biotech, Inc. 2025. 5. Daneshmand S, et al. *Urol. Oncol*. 2025;S1078-1439. 6. Jacob JM, et al. AUA 2025. Oral presentation. 7. Daneshmand S, et al. *J Clin Oncol*. 2025 Jul 30;101200/JCO2501651. doi: 10.1200/JCO-25-01651.